A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival (vol 104, 106555, 2021)

导出原文传递

翻译打印收藏纠错

作者： Garcia, Jacqueline S. ^[1] ; Swords, Ronan T. ^[2] ; Roboz, Gail J. ^[3] ; Jacoby, Meagan A. ^[4] ; Garcia-Manero, Guillermo ^[5] ; Hong, Wan-Jen ^[6] ; Yang, Xiaoqing ^[7] ; Zhou, Ying ^[8] ; Platzbecker, Uwe ; Steensma, David P. ; Wolff, Johannes E. ; Fenaux, Pierre

作者单位： Univ Paris, Hop St Louis, AP HP, Paris, France ^[1] Cornell Univ, Weill Med Coll, Ithaca, NY 14853 USA ^[2] Genentech Inc, San Francisco, CA 94080 USA ^[3] Washington Univ, Sch Med, St Louis, MO USA ^[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA ^[5] Dana Farber Canc Inst, Boston, MA 02115 USA ^[6] Leipzig Univ Hosp, Leipzig, Germany ^[7] AbbVie Inc, N Chicago, IL USA ^[8]

发布时间 2021-09-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Leukemia Research

2021年105卷

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival (vol 104, 106555, 2021)

Leukemia Research

相似文献

Leukemia Research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival (vol 104, 106555, 2021)

Leukemia Research

相似文献

Leukemia Research

相关期刊

检索历史清除